Check-Cap Ltd. (NASDAQ:CHEK) was upgraded by equities research analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a report released on Thursday.

CHEK has been the subject of several other reports. Zacks Investment Research cut shares of Check-Cap from a “buy” rating to a “hold” rating in a research note on Tuesday, May 23rd. Maxim Group reaffirmed a “buy” rating on shares of Check-Cap in a research report on Tuesday, May 30th. Finally, HC Wainwright set a $6.00 price target on shares of Check-Cap and gave the stock a “buy” rating in a research report on Friday, August 11th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $5.00.

Check-Cap (CHEK) traded up 2.94% on Thursday, reaching $1.75. The company’s stock had a trading volume of 32,573 shares. Check-Cap has a 52 week low of $1.65 and a 52 week high of $2.95. The stock’s market capitalization is $29.71 million. The firm has a 50 day moving average price of $1.83 and a 200 day moving average price of $2.04.

Check-Cap (NASDAQ:CHEK) last announced its quarterly earnings data on Thursday, August 10th. The medical research company reported ($0.17) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.16) by $0.01. On average, equities analysts anticipate that Check-Cap will post ($0.63) EPS for the current year.

WARNING: This piece was posted by American Banking News and is the property of of American Banking News. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this piece can be accessed at

An institutional investor recently raised its position in Check-Cap stock. Knott David M boosted its position in Check-Cap Ltd. (NASDAQ:CHEK) by 1.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 162,871 shares of the medical research company’s stock after buying an additional 3,000 shares during the period. Knott David M owned about 1.05% of Check-Cap worth $349,000 as of its most recent filing with the SEC. 13.35% of the stock is currently owned by hedge funds and other institutional investors.

About Check-Cap

Check-Cap Ltd. (Check-Cap) is a clinical-stage medical diagnostics company. The Company is engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The Company’s system consists of main components, such as ingestible scanning capsule; Capsule Positioning System (CPS), a recorder worn on the patient’s back, and a personal computer (PC)-based work station for data reconstruction and image processing.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Check-Cap Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check-Cap Ltd. and related companies with's FREE daily email newsletter.